Table 5 Incidence of adverse drug reactions

Number of patients who experienced adverse drug reactions (%)

18

(22.0)

4

(23.5)

14

(21.5)

Number of adverse drug reactions

28

4

24

Infections and infestations

7

(8.5)

2

(11.8)

5

(7.7)

Acute sinusitis

1

(1.2)

0

(0.0)

1

(1.5)

Bronchitis

2

(2.4)

0

(0.0)

2

(3.1)

Gastroenteritis

1

(1.2)

0

(0.0)

1

(1.5)

Herpes simplex

1

(1.2)

1

(5.9)

0

(0.0)

Influenza

1

(1.2)

0

(0.0)

1

(1.5)

Nasopharyngitis

1

(1.2)

1

(5.9)

0

(0.0)

Otitis media acute

1

(1.2)

0

(0.0)

1

(1.5)

Pneumonia

1

(1.2)

0

(0.0)

1

(1.5)

Subcutaneous abscess

1

(1.2)

0

(0.0)

1

(1.5)

Varicella

1

(1.2)

0

(0.0)

1

(1.5)

Fungal esophagitis

1

(1.2)

0

(0.0)

1

(1.5)

Immune system disorders

1

(1.2)

0

(0.0)

1

(1.5)

Hypersensitivity

1

(1.2)

0

(0.0)

1

(1.5)

Eye disorders

1

(1.2)

1

(5.9)

0

(0.0)

Chalazion

1

(1.2)

1

(5.9)

0

(0.0)

Ear and labyrinth disorders

1

(1.2)

0

(0.0)

1

(1.5)

Ear discomfort

1

(1.2)

0

(0.0)

1

(1.5)

Respiratory, thoracic, and mediastinal disorders

2

(2.4)

0

(0.0)

2

(3.1)

Upper respiratory tract inflammation

2

(2.4)

0

(0.0)

2

(3.1)

Gastrointestinal disorders

4

(4.9)

0

(0.0)

4

(6.2)

Abdominal pain

1

(1.2)

0

(0.0)

1

(1.5)

Stomatitis

3

(3.7)

0

(0.0)

3

(4.6)

Skin and subcutaneous tissue disorders

1

(1.2)

0

(0.0)

1

(1.5)

Dry skin

1

(1.2)

0

(0.0)

1

(1.5)

Erythema

1

(1.2)

0

(0.0)

1

(1.5)

Perioral dermatitis

1

(1.2)

0

(0.0)

1

(1.5)

Musculoskeletal and connective tissue disorders

1

(1.2)

1

(5.9)

0

(0.0)

Arthritis

1

(1.2)

1

(5.9)

0

(0.0)

Investigations

3

(3.7)

0

(0.0)

3

(4.6)

Transaminases increased

1

(1.2)

0

(0.0)

1

(1.5)

Hepatic enzyme increased

1

(1.2)

0

(0.0)

1

(1.5)

Matrix metalloproteinase-3 increased

1

(1.2)

0

(0.0)

1

(1.5)